1. Ingeniería

Methods
DNA extraction and bisulfite conversion
The genomic DNA was extracted from the tissue samples using the TIANamp
Genomic DNA Kit (TianGen Biotech, Beijing, China) according to the manufacturer’s
instruction. Sodium bisulfite conversion of 500 ng genomic DNA extracted from the
breast tissues was carried out using the EZ DNA Methylation-LightningTM Kit (Zymo
Research, Irvine, CA, USA) according to the manufacturer’s instruction. All DNA
samples after bisulfite conversion were quantified using a Nanodrop 2000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
Bisulfite sequencing primer (BSP) design
The 5’ promoter sequence for each candidate gene was obtained from UCSC
genome browser (http://genome.ucsc.edu/cgi-bin/hgGateway). The target-specific
bisulfite sequencing primers (BSP) were designed for each gene using the online
design
tool,
Methprimer
(http://www.urogene.org/methprimer/),
with
default
parameters (Online Resource Table 2). Total 48 amplicons were designed for the
promoter regions of the 48 candidate genes and covered an average of 13 CpG sites
per amplicon (ranged from 4 to 37) with amplicon size around 300 bp or less. The
universal sequencing tags were added to the 5’-end of the forward and reverse primers
by following the User Guide of Access ArrayTM System for Illumina Sequencing
Systems (Fluidigm, South San Franciso, CA, USA). All primers were validated by
single-plex PCR and assessment of PCR products for expected size on agarose gel.
1
High-throughput microfluidic PCR for target enrichment and next generation
bisulfite sequencing
The Access ArrayTM system (Fluidigm, South San Franciso, CA, USA) was used
for target enrichment to prepare sequencing libraries, which can simultaneously apply
48 distinct microfluidic PCR reactions on 48 samples to enrich target gene regions.
Total 50 ng of each bisulfite treated DNA sample was amplified using bisulfite
sequencing primers on the 48.48 Access Array IFC according to the manufacturer’s
2-Primer Target-Specific PCR Amplification protocol. Total 48 primer pairs were used
to amplify 48 distinct regions in 48 bisulfite treated DNA samples on each Access
Array. We divided the 180 patient sample pairs into the discovery set (89 sample pairs)
and the validation set (91 sample pairs), then amplified the bisulfite treated DNA on 4
Access Array IFCs for each set.
After microfluidic PCR, the 48 products for each sample were pooled
automatically on the Access Array and harvested from their original sample wells.
The sample-specific 10-base barcodes and sequencing tags were added to each PCR
product pool according to the manufacturer’s protocol. Equal volume of each
barcoded product was pooled into amplicon libraries and purified using Agencourt
AMPure XP system (Beckman Coulter, CA, USA) then examined on Agilent
Bioanalyzer 2100 for product size distribution. The purified libraries were quantified
with Qubit® dsDNA HS Assay Kit (Life Technologies, CA, USA) and sequenced on a
MiSeq sequencer using MiSeq Reagent Kit v2 (300 cycles). We pooled the libraries
2
by the discovery set and the validation set separately, then sequenced them in two
separate runs on MiSeq sequencer. In addition, to evaluate the reproducibility of the
method, 10 repeated DNA samples of 4 random selected tumor/normal pairs and the
Human Methylated & Non-methylated DNA Set were included in both runs.
Sequencing data alignment and methylation analysis
After MiSeq sequencing, the paired-end read data were demultiplexed according
to sample-specific barcodes with default parameters by using MiSeq Reporter
software. The sequencing reads were mapped to each gene reference sequence using
the BiQ Analyzer 3.0 software [1] with default parameters. The methylation status and
methylation level of each analyzed CpG-site in each gene were returned from the
software. The methylation level for each gene was assigned by averaging the
methylation level of all CpG sites in the gene for each sample.
Figure Legends
Online Resource Fig. 1 Unsupervised hierarchical clustering of the discovery set (a)
and the validation set (b) based on the methylation levels of the 48 candidate genes.
Heat map and clustering of 48 genes show significant differences between tumors (red)
and normal tissues (green). Heat-map colors symbolize DNA methylation, as
indicated in the color key
Reference for Online Resource
3
1. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T (2005) BiQ
Analyzer: visualization and quality control for DNA methylation data from bisulfite
sequencing. Bioinformatics 21 (21):4067-4068
4
Online Resource Table 1 DAVID functional annotation of candidate genes
Wnt
fatty acid regulation regulation regulation regulation of response to
tumor
phosphorylatio estrogen signal signaling
of cell
of cell
metabolic of
Gene
suppressor
stimulus
pathway
proliferation n
apoptosis cycle
process
ACADL
x
ADAMTSL1
x
APC
x
x
x
x
x
x
BMP6
x
BRCA1
x
x
x
x
x
x
BRCA2
x
x
x
x
x
CADM1
x
x
x
CAV1
x
x
x
CCND2
x
x
x
x
x
CDH1
x
x
CDKN2A
x
x
x
x
x
COL1A2
x
CST6
x
DBC1
x
x
DIRAS3
x
x
EGFR
x
x
x
x
x
x
ESR1
x
x
ESR2
x
x
GREM1
x
GSTP1
x
HIC1
x
HRAS
x
x
ICAM5
x
IGFBP3
x
x
x
x
LAMA3
x
MGMT
x
MLH1
x
x
NPY
x
PDGFRB
x
x
x
PGR
x
PPM1E
x
PRKCDBP
x
PTGS2
x
x
x
x
x
x
RASSF1
x
RECK
x
x
RUNX3
x
x
x
SFN
x
x
x
x
SFRP1
x
x
x
SFRP2
x
x
SOX17
x
SYK
x
x
x
TERT
x
TGFBR2
x
x
x
x
THBS1
x
x
x
x
TIMP3
x
x
x
TNFRSF10D
x
x
WIF1
x
x
WRN
x
11
4
23
11
18
12
8
23
6
Total
Online Resource Table 2 List of the bisulfite sequencing primers*
Gene name
ACADL
ADAMTSL1
APC
BMP6
BRCA1
BRCA2
CADM1
CAV1
CCND2
CDH1
CDKN2A
COL1A2
CST6
DBC1
DIRAS3
EGFR
ESR1
ESR2
GREM1
GSTP1
HIC1
HRAS
ICAM5
IGFBP3
LAMA3
MGMT
MLH1
NPY
PDGFRB
PGR
F-primer (5'-3')
AAATAAGAAAGAATGTTGTAAGTAAAGGTA
TGGGAAGTATAGTGTTTGGTTTTATTTT
GGGTTAGGGTTAGGTAGGTTGTG
TAATTTAGGTTTTTTAAATGATGGTAAAAG
GGTAGATTGGGTGGTTAATTTAGAGT
GTTGGGATGTTTGATAAGGAATTT
GGGGATTTGTTTTTTTATTTTTTATTTT
AGAGTAGGGAAAATGTTGTTTTAGGTT
AAGTGATGTTTAGAGGTTGGGAGTT
GTATTTTGGGAGGTTAAGGTAGGAG
GGTAGGTGGGGAGGAGTTTAGTT
AGGGTTTAGGTTTAGGGTAGAATTG
TTTTTGTATTGGTATTTGTTGTTGG
TTAGGGGATTAGGGATTTGTATTGT
TTGTTGTATTTTTTAGATGGTAAAAAGTAA
GGGTGTTTGATAAGATTTGAAGGAT
GAGATTAGTATTTAAAGTTGGAGGTT
GAGGGTGTTTTTATTTAGAGGTTA
GTTTTTTTTAGAGGGGAAGAATG
AAATATAAAAATTAGTTAGATGTGGTA
GTATAGGGGGATTTTAGGGTTTTAT
TTAGGTTGGTTTTGAATTTTTGATT
TAGTTAGGGTTGGGGTAGGG
GGTTTTTGGGGATATAAATAGTTTAG
GATTTAATTAATTTTTGTTTTGG
TTATATATTTTGTTTTAAAAATTATTTTTG
TTTTTTAGGAGTGAAGGAGGTTA
TGTTTTTATTTTTGGTAGGATTAGA
GAGAAATGATTTTTTTGGGTGTTAT
GGAGAATTTTTTTGGAGAATTTTT
CpG sites in
R-primer (5'-3')
product
CCACCTATAATATCCTCCCAAAAA
10
CCAACCAATCAAACTCCTACTAATC
6
CAACACCTCCATTCTATCTCCAATA
17
ACTCAAATACCTCACTCCAACCC
4
ACCCAAAACAAAAAATAAAAACCTC
15
ATCACAAATCTATCCCCTCAC
27
TCTCCCTTAAAAAAATCCTCTATCC
16
TAAACACATCCCCAAAATTCTAACA
16
AACCCCCATAAAAAAATTACTCCA
7
AACTAAAAATACAAATACACACCACCAC
15
TCCCTCAAATCCTCTAAAAAAACC
13
AACTCATTCCAAAAAAAATCTTTTAAA
5
AAATTCAAAAAACCCAAAAAACC
13
AAATTCTCTAAAAACCACCAAAAAC
4
CACAAATTCTCCCACACTTAACTAAC
4
ACAAAACAAACTTATACCAACTTTAAACAA
16
TTAATATAAAAAATCATAATCATAATCC
12
AAATTTCAAAAAACAATTATTTCTC
17
TTCTCTACCCCAAATCTAAACTTTC
21
TATAACCCAAACTAAAATACAATAAC
37
AACCTAAACAAAAATATTACCCACAC
7
AAACTCACCCCAAACACATAAAC
7
TAATAACCCAAAACCTTCTAAAAAC
8
AATCACTCCTAACCAACTCAACAC
15
AACCTCTCAACTCTAAAACCTACC
25
CCTACCATCAATAAAAAACATACC
6
CCCAAAAAAAACAAAATAAAAATC
13
ACTTAAAAAACCACCCACACC
5
AATACTTAAAAATTCCACAACCCAC
6
CTAATCAACTCCTACCCTTAACCTC
11
PPM1E
AGGGTAGGGTATTTAATTAATAAAGATATT TTCTAATTAAACATTACAAAATCCCTC
PRKCDBP
TTTGGGGTTAATAGGTTTTTTAGTAG
CCCAACTCCAACTATAACTCAAAC
PTGS2
AGATTTTTGGAGAGGAAGTTAAGTGT
AAAAAATAATCCCCACTCTCCTATC
RASSF1
TTTTTGTAGATTGTAAGTTTATTTGTTATT
CCTACACTATAACCTACCCATCCTC
RECK
TTTAGTGATGAATTTTTGTTAGGGG
CCAAAAAAACTTCTCTCCTTCATATAC
RUNX3
GGTTTTGGGTTGTGGTATTG
ACAAATCCTCCAAAATCAAATAAC
SFN
TTTTTTGAATTTTTATGGGTTTTGT
AAACTCCAAACTACCCCCTCTTAT
SFRP1
TTAGTTTGGTTAATATGGTGAAATTT
ACAAACCCATAAAATTATAAAAACTTTTT
SFRP2
TTATGTTTGGTAATTTAGTAGAAATTT
ACAACAAACAAAAAAACCTAACC
SOX17
TGGTTATATTTGTGTAGAAAAGGTTT
AAAAAATAAAACACTAAAATACCCC
SYK
GGGTAGTTTTATTTTTTTTGTTTG
ACTCTTCCTCATTTTAAACAACTTC
TERT
TTGAGAATTTGTAAAGAGAAATGA
AATATAAAAACCCTAAAAACAAATAC
TGFBR2
TTGTTATTTTGTGAATTGTGTGTATT
CAACAACTAAACAAAACCTCTCTC
THBS1
GGTTTTTTTAGGTGGTTTTTTTAGTTT
AAACCAATCTAAACTCCTCTCTCC
TIMP3
TGGTTTGGGTTAGAGATATTTAGTG
TTCAAATCCTTATAAAAAATAATACC
TNFRSF10D
GATTTAGTTTGAGTGTTTGGAAGTG
TTATCCCCAAAATCCCATAAA
WIF1
GTTTTGGTTGAGGGAGTTGTA
ACCAACAAACACAAAAAAATACTC
WRN
TTGGGTTTGGGGATAGAGTTTAT
ACTTACAACTAAAAATAAAAAAAACCAAAC
*The universal sequencing tags were added to the 5’-end of the forward and reverse primers by following
the User Guide of Access ArrayTM System for Illumina Sequencing Systems (Fluidigm, South San Franciso, CA, USA).
6
13
10
28
8
32
4
11
9
16
30
26
7
21
15
12
13
8
Online Resource Table 3 The methylation level of the 48 genes in the discovery set and the validation set
The Discovery Set Methylation level (Mean ± SD)
T-test p Corrected
1
Tumor
Normal Difference
value2
p value3
Gene
71.7±8.7 68.6±3.9
3±8.5
0.0013
0.0208
ACADL
10.8±12.4 1.83E-12
6.04E-11
ADAMTSL1 16.3±11.6 5.5±3.3
14.4±15.1
2.1±4
12.3±14.7 6.37E-12
1.97E-10
APC
56.1±7.7 60.5±5.9
-4.4±9.7
5.24E-05
9.43E-04
BMP6
2.2±7
1±1.6
1.2±6
0.0657
0.6570
BRCA1
0.8±0.4
0.7±0.3
0.1±0.5
0.1629
1
BRCA2
3.7±4.4
2.4±2.1
1.3±4.9
0.1778
0.0127
CADM1
3.2±3.6
0.9±0.4
2.3±3.7
8.57E-08
2.06E-06
CAV1
12.8±9.6
3.4±2.6
9.4±10.2
1.47E-13
5.15E-12
CCND2
9.8±3.6
9.7±2.1
0±4.5
0.9219
1
CDH1
4.3±8.8
5.2±6.7
-0.9±11.2
0.4707
1
CDKN2A
54.1±13 45.2±10.8 8.9±16.5
2.18E-06
4.58E-05
COL1A2
16.8±11.6 10.8±5.3
6±12.5
1.62E-05
3.08E-04
CST6
22.8±9.3 18.4±6.8
4.4±10.9
2.40E-04
0.0041
DBC1
70.3±14.6 81.1±8.2 -9.9±13.9
6.21E-08
1.61E-06
DIRAS3
23.5±8.2
13.2±4
10.3±8.8
3.11E-18
1.31E-16
EGFR
8.3±5.7
10.5±5.7
-2.2±8.1
0.1833
0.0141
ESR1
3.6±7.5
2±1.9
1.6±7.8
0.0553
0.6083
ESR2
21±11.2
9.1±5.7
11.9±12.3 2.65E-14
9.54E-13
GREM1
16.6±3.3 14.6±1.9
2±3.8
4.29E-06
8.58E-05
GSTP1
4.7±6.6
2.9±1.3
1.8±6.5
0.1485
0.0099
HIC1
25.3±8.4 40.3±7.4
-15±10.5
3.96E-23
1.86E-21
HRAS
13.2±12.2
3±2.4
10.1±11.9 3.46E-12
1.11E-10
ICAM5
20.8±10.8 7.9±5.2
12.9±12
2.31E-16
9.24E-15
IGFBP3
1.7±2.4
1.7±2.9
0±4
0.9361
1
LAMA3
94.1±5.1 94.7±2.1
-0.7±5.3
0.2365
1
MGMT
0.7±0.3
0.7±0.3
0±0.4
0.6942
1
MLH1
12.9±7.5
3.2±2.3
9.8±7.7
4.95E-20
2.23E-18
NPY
20.3±11.4 7.2±4.5
13.1±12
7.82E-17
3.21E-15
PDGFRB
4.6±3.5
2±1.3
2.6±4
1.55E-08
4.34E-07
PGR
17.8±10.8 10.4±3
7.4±10.8
5.74E-09
1.66E-07
PPM1E
The Validation Set Methylation level (Mean ± SD)
T-test p Corrected
1
Tumor
Normal Difference
value2
p value3
72.9±8.6 70.3±7.9
2.6±12.8
0.0546
0.4212
17.3±13.6
6±2.8
11.2±14.1 3.71E-11 1.26E-09
11.3±15.1 1.9±3.9
9.4±14.5
3.67E-08 1.06E-06
55.5±8.6 61.4±5.7
-5.9±10.6
8.04E-07 2.01E-05
2.7±10.2
0.7±0.7
2±10.3
0.0751
0.4212
0.9±1.4
0.7±0.5
0.2±1.5
0.1613
0.4839
3.2±3.9
2.2±2.6
0.9±4.5
0.0517
0.4212
3.1±5.1
1±0.7
2.1±5
1.10E-04
0.0019
14.4±11.9 3.7±2.3
10.5±11.9 3.96E-12 1.46E-10
9.9±3.7
8.9±2.3
1±4.7
0.4212
0.0468
19.9±10.5 15.3±6.1
4.6±12.7
8.84E-04
0.0133
57.4±15.9 46.3±10.3
11±19.7
7.17E-07 1.86E-05
14.8±11.2
9±4.2
5.9±11.9
1.11E-05 2.55E-04
25.5±12.1 19.1±6.6
6.2±13.8
9.17E-05
0.0017
74.6±15.3 82.1±8.5
-7.7±16.4
7.01E-04
0.0112
24.2±11 12.5±4.2
11.8±11.7 1.99E-14 8.76E-13
7.2±4.7
11.2±5.7
-4.1±6.7
3.54E-07 9.56E-06
4.3±11.3
1.9±1.8
2.2±11.2
0.0859
0.4212
20±14
10.2±5.4
9.8±15.3
3.11E-08 9.33E-07
17.1±4.7 14.2±3.3
2.9±4.8
1.74E-07 4.87E-06
4±4.4
2.5±2.1
1.4±4
0.001
0.0140
28.3±10.6 41.7±6.4 -13.7±11.9 5.20E-17 2.44E-15
13.4±12.3 2.9±2.5
10.4±12.1 1.34E-12 5.23E-11
18.5±10.9 9.2±4.7
9.2±11.4
9.32E-11 3.08E-09
1.5±1.8
1±1.2
0.5±2.3
0.4100
0.0410
94.9±2.3
95±2.2
-0.1±3
0.7554
0.7554
0.8±0.5
0.7±0.3
0.1±0.6
0.0508
0.4212
13.4±10.8 3.6±2.1
9.7±10.4
5.10E-14 2.14E-12
20.8±12.6
8.1±4
12.7±12.9 4.48E-15 2.02E-13
4.7±4.5
2.2±1.8
2.6±5
3.63E-06 8.71E-05
18±11.1 10.2±3.1
7.7±10.8
1.86E-09 5.95E-08
PRKCDBP
PTGS2
RASSF1
RECK
RUNX3
SFN
SFRP1
SFRP2
SOX17
SYK
TERT
TGFBR2
THBS1
TIMP3
TNFRSF10D
WIF1
WRN
1
2
8.8±7.1
11.4±8.9
0.9±0.6
52.5±9.7
13.5±13.3
32.8±5.6
17.5±10.4
28.7±16.3
26.1±10.6
2.8±2.9
38.2±16
1.7±0.9
1.7±1.8
10.8±7.4
20±14
6.7±6.8
26.1±10.9
4.1±3.1
2.5±2.2
1.3±2.3
50.5±6.5
3.6±3.9
46.6±8.7
6.8±3.2
7±6.6
9.6±4.9
3.5±3.1
16.3±9.6
1.1±0.6
1.6±1.7
5.6±4.8
6.2±4.5
2.3±1.6
11.7±5.9
4.7±7.2
8.8±9.1
-0.4±2.5
1.9±8.8
9.8±13.2
-13.8±9.6
10.7±10.7
21.8±17.5
16.4±11.6
-0.7±4.5
21.8±20.7
0.6±1.1
0.1±2.5
5.1±9.3
13.8±15.1
4.4±7
14.5±12.3
2.10E-08
1.60E-14
0.1707
0.0425
4.03E-10
3.07E-23
5.28E-15
1.63E-19
7.17E-23
0.1416
7.76E-16
1.32E-06
0.8134
1.24E-06
2.25E-13
6.53E-08
2.47E-18
5.67E-07
5.92E-13
1
0.5100
1.21E-08
1.47E-21
2.01E-13
7.17E-18
3.30E-21
1
3.03E-14
2.90E-05
1
2.85E-05
7.65E-12
1.63E-06
1.06E-16
9±8.5
3.3±2.8
13.3±12.2
3±2.7
1.5±3.9
1±0.3
53.9±10.2 51.1±5.9
8.6±11.8
2.8±2
36.2±7.1
43.6±8
16.9±11.2 7.1±3.8
28±21.1
6.3±6.2
24.8±11.9
9.4±5
3.3±3.1
4.2±3.1
39.1±19.3 18.1±10.8
1.5±1.2
0.9±0.4
1.6±2.1
1.1±0.5
10.4±12.3 4.4±3.4
18.7±15.3 6.1±4.8
5.2±5.3
2.4±1.7
26.8±11.3 12.9±6.1
5.7±8.8
10.3±11.9
0.5±3.9
2.8±9.7
5.9±11.8
-7.5±9.2
9.7±11.5
21.6±23.5
15.6±12.8
-0.8±3.4
20.9±21
0.7±1.3
0.6±2.1
6±12.9
12.6±15
2.8±5.7
13.9±13
1.83E-08
9.69E-13
0.2428
0.0071
1.77E-05
1.15E-11
3.90E-12
4.36E-13
1.22E-18
0.0277
3.45E-14
1.72E-05
0.0171
5.45E-05
3.84E-12
1.24E-05
1.49E-15
5.67E-07
3.88E-11
0.4856
0.0923
3.61E-04
4.03E-10
1.46E-10
1.79E-11
5.86E-17
0.3047
1.48E-12
3.61E-04
0.2052
0.0010
1.46E-10
2.73E-04
6.85E-14
Difference: the mean of tumor methylation level minus the mean of normal methylation level;
p value calculated with paired T-test; 3 Corrected p value using the Holm's procedure; p value<0.05 in bold; SD, standard deviation.
Online Resource Table 4 Correlation of the gene methylation level with each breast cancer subtypes in tumor tissues
Methylation level (mean±SD)
Non-BasalCorrected
Gene
Basal-like
like
p value1
(n=23)
p value2
(n=157)
ACADL
65.8±10.9 73.2±7.9 1.25E-04 0.0235
ADAMTSL1 9.1±7.5
17.8±12.9
0.0012
0.2187
APC
7.8±12.2 13.4±15.4
0.0546
1
BMP6
60.4±11.2 55.1±7.4
0.0303
1
BRCA1
6.6±18.9
1.8±5.6
0.7922
1
BRCA2
0.7±0.3
0.9±1.1
0.4418
1
CADM1
3.3±4.7
3.5±4.1
0.8859
1
CAV1
2.5±6.4
3.3±4.1
0.0055
0.9495
CCND2
8.6±9.1
14.1±10.7
0.0075
1
CDH1
9.9±4
9.8±3.6
0.9402
1
CDKN2A
16.5±15.1 11.5±11.9
0.0893
1
COL1A2
61.7±16.2 54.9±14.1
0.0552
1
CST6
10.2±6.4 16.5±11.8
0.0114
1
DBC1
22.7±11.3 24±11.1
0.5702
1
DIRAS3
70±20.9 72.8±16.2
0.6840
1
EGFR
22.2±11.7 23.5±9.8
0.2430
1
ESR1
8.1±6.8
7.7±5.4
0.9198
1
ESR2
2±2.9
4±9.7
0.2870
1
GREM1
19±15.6 20.6±12.3
0.2870
1
GSTP1
15.3±3.4
17.1±4.2
0.0158
1
HIC1
4.9±6
4.2±5.5
0.7366
1
HRAS
24±8.2
27.1±10.5
0.2009
1
ICAM5
6.7±8.1
14.2±12.4 4.75E-04 0.0879
IGFBP3
12.1±8.8
20.4±11 5.58E-04 0.1026
LAMA3
1.9±2.5
1.6±2.1
0.6824
1
MGMT
92.5±8.4
94.8±2.8
0.4444
1
MLH1
0.6±0.3
0.7±0.4
0.3763
1
NPY
7.1±7.7
14±9.2
5.48E-05 0.0104
PDGFRB
18.5±16 20.9±11.3
0.1134
1
PGR
5.3±5.9
4.6±3.7
0.8421
1
PPM1E
11.8±6.4 18.7±11.2
0.0016
0.2923
PRKCDBP
6.5±5.6
9.2±8
0.1134
1
PTGS2
5.1±6.5
13.4±10.8 8.59E-06 0.0016
RASSF1
2.6±7.6
1±0.7
0.1245
1
RECK
49.1±14.9 53.8±8.9
0.1644
1
RUNX3
3.6±6
11.7±13.1 4.69E-05 0.0090
Methylation level (mean±SD)
HER2- Non-HER2Corrected
enriched
enriched p value1
p value2
(n=17)
(n=163)
72.5±5.2
72.2±8.9
0.6265
1
11.3±12.7 17.3±12.5
0.0164
1
13.9±16.8
12.6±15
0.6758
1
57.3±10.9
55.6±7.9
0.5788
1
0.7±0.4
2.6±9
0.6580
1
0.7±0.2
0.9±1.1
0.3514
1
3.4±4.1
3.4±4.1
0.8737
1
1.2±1
3.4±4.6
0.0051
0.8934
13.1±12.9 13.4±10.5
0.5361
1
10.9±4.6
9.7±3.5
0.3365
1
16.5±14.4 11.7±12.2
0.1655
1
58.9±16.7 55.4±14.3
0.4646
1
15.7±9.7
15.7±11.6
0.6830
1
22.8±12.6
23.9±11
0.5990
1
80.4±13.1
71.6±17
0.0655
1
18.9±10.3
23.8±9.9
0.0684
1
9.3±5.6
7.6±5.6
0.1957
1
7.7±20.9
3.3±6.8
0.6884
1
19.2±13.5 20.5±12.7
0.6024
1
17.2±4.5
16.8±4.1
0.5297
1
2.8±2
4.5±5.8
0.3907
1
31.3±12.4
26.2±9.9
0.1794
1
15.1±13.7 13.1±12.1
0.6058
1
18.3±10.6 19.5±11.1
0.7083
1
1.4±0.9
1.6±2.2
0.4324
1
95.2±1.8
94.4±4.2
0.7302
1
0.8±0.5
0.7±0.4
0.4706
1
12.8±10.8
13.2±9.1
0.6196
1
17.7±9.8
20.9±12.2
0.4353
1
6.1±4.5
4.5±4
0.0620
1
17.8±14.9 17.8±10.5
0.3934
1
12.4±10
8.5±7.5
0.1377
1
11±12.6
12.5±10.6
0.2700
1
0.9±0.4
1.2±2.9
0.9551
1
55.9±10.8
52.9±9.8
0.4827
1
4.7±9.7
11.3±12.9
0.0019
0.3431
Methylation level (mean±SD)
NonCorrected
Luminal
Luminal p value1
A (n=55)
p value2
A (n=125)
75.2±7.8
71±8.7 2.24E-04 0.0418
18±13.4 16.1±12.3 0.4440
1
11.9±15
13±15.2
0.9221
1
55.1±6.9 56.1±8.7
0.7152
1
1.1±1.8
2.9±10.2
0.2603
1
1.2±1.8
0.7±0.4
0.2113
1
2.6±2.3
3.8±4.7
0.2696
1
3.6±4.3
3±4.5
0.0162
1
13.3±10.7 13.4±10.7 0.9381
1
9.9±3.3
9.8±3.7
0.5014
1
14.8±11.4 11±12.8
0.0130
1
53.6±15.3 56.7±14.2 0.2805
1
14.6±10.3 16.2±11.9 0.4703
1
22.7±11 24.3±11.2 0.3548
1
72.1±17.3 72.6±16.7 0.9851
1
23.8±9.4 23.1±10.3 0.5541
1
7±5.4
8.2±5.7
0.1074
1
2.7±6
4.2±10.2
0.1496
1
18.4±12.4 21.3±12.8 0.1466
1
16.6±4
16.9±4.2
0.6967
1
3.4±2.7
4.7±6.4
0.9567
1
29.4±10.4 25.6±10
0.0095
1
14.8±13.3 12.6±11.7 0.2436
1
20.2±10.8 19±11.2
0.5376
1
1.2±1.7
1.8±2.3
0.0190
1
95±3
94.3±4.4
0.1545
1
0.8±0.5
0.7±0.4
0.8340
1
13.3±8.6 13.1±9.6
0.6095
1
18.8±10.4 21.4±12.6 0.2159
1
3.1±2.3
5.4±4.4 1.30E-04 0.0243
19.6±11.7 17±10.5
0.1406
1
8±5.7
9.3±8.6
0.9641
1
13.9±11.6 11.7±10.3 0.1618
1
1±0.5
1.3±3.3
0.5879
1
53±8.5
53.3±10.5 0.7835
1
10.2±10.4 10.9±13.6 0.0681
1
Methylation level (mean±SD)
NonCorrected
Luminal B
Luminal B p value1
(n=79)
p value2
(n=101)
71.9±8.5 72.5±8.8
0.5120
1
19.6±12.5 14.4±12.4 0.0012
0.2187
14±15.7 11.6±14.7 0.4024
1
54.6±7.1 56.7±8.9
0.1600
1
2.5±7.7
2.3±9.3
0.9598
1
0.8±0.4
1±1.4
0.7370
1
3.6±4.3
3.3±4
0.9368
1
3.6±4.4
2.8±4.5
0.1750
1
14.5±10.6 12.5±10.7 0.1335
1
9.6±3.6
10±3.6
0.3586
1
9±11.2
14.7±12.9 0.0011
0.1927
54.7±12.9 56.5±15.7 0.4288
1
18.3±13.3 13.7±9.3
0.0303
1
25.2±11.1 22.7±11
0.0787
1
71.5±16.2 73.2±17.4 0.4105
1
24.3±10.1 22.6±10
0.1723
1
7.8±4.9
7.8±6.1
0.5711
1
4.3±8.2
3.3±9.8
0.0294
1
23.1±11.9 18.3±13
0.0039
0.6824
17.4±4.4 16.4±3.8
0.0977
1
5.1±7.3
3.7±3.7
0.8797
1
25±9.9
28.1±10.4 0.0573
1
14.1±11.9 12.6±12.4 0.2299
1
21±11.3 18.1±10.8 0.0775
1
1.9±2.5
1.4±1.8
0.2471
1
94.6±2.9 94.4±4.7
0.6602
1
0.7±0.3
0.7±0.4
0.8210
1
14.7±9.4
11.9±9
0.0254
1
23.1±12 18.6±11.6 0.0059
1
4.9±3.6
4.5±4.3
0.1220
1
18.2±10.1 17.5±11.5 0.3321
1
9.6±9.1
8.3±6.6
0.9231
1
14.1±10.1 11±11.1
0.0065
1
1±0.9
1.3±3.6
0.1971
1
53.5±8.7 52.9±10.8 0.8143
1
14.5±15
7.7±9.6
0.0040
0.6973
SFN
SFRP1
SFRP2
SOX17
SYK
TERT
TGFBR2
THBS1
TIMP3
TNFRSF10D
WIF1
WRN
1
36.1±8.2
13.6±9.7
16.7±19.4
22.9±13.3
2.2±2.7
36.8±22.8
1.5±1.1
1.1±0.8
5.5±3.9
15.5±15.8
4.9±4
22.9±11
34.3±6.3
17.7±10.8
30±18.3
25.9±11.2
3±3
38.6±17.1
1.6±1.1
1.7±2
11.1±10.5
19.9±14.4
6.1±6.3
26.2±11.5
0.1469
0.0429
2.82E-04
0.2430
0.0594
0.5908
0.6481
0.0736
0.0016
0.0934
0.4970
0.2643
1
1
0.0524
1
1
1
1
1
0.2923
1
1
1
35.5±5.7
23±14.8
29.5±23.1
28.8±12.1
3.3±3.5
37.1±22.4
1.6±1
2.2±3.9
8.2±5.7
15.8±14.7
5.6±5
25.6±11.2
34.4±6.7
16.6±10.1
28.2±18.5
25.1±11.4
2.8±2.9
38.5±17.4
1.6±1.1
1.6±1.6
10.7±10.4
19.7±14.6
6±6.2
25.8±11.6
0.5075
0.0634
0.9746
0.1114
0.9085
0.6230
0.8163
0.9785
0.5169
0.2434
0.8930
0.7192
1
1
1
1
1
1
1
1
1
1
1
1
35.1±6.7
16.8±8.7
31.1±18.6
22.6±10
2.8±2.5
41.1±16.9
1.3±0.8
1.6±1.6
11±10.4
19±15.6
5.7±6.3
26.5±13
34.2±6.5
17.4±11.5
27.1±19
26.8±11.9
2.9±3.2
37.1±18.2
1.7±1.2
1.7±2.1
10.2±9.9
19.5±14.2
6±6
25.5±10.8
0.3523
0.7644
0.1864
0.0163
0.8437
0.2194
0.0470
0.7175
0.7573
0.7526
0.9270
0.8170
p value calculated with Kruskal-Wallis Rank Sum Test and 2 Corrected p value using the Holm's procedure for all 4*48 testings, p -value<0.05 in bold
1
1
1
1
1
1
1
1
1
1
1
1
33.5±6.3
17±10.9
29.7±17.2
27.6±11.7
3.2±3.3
37.2±16.4
1.7±1.3
1.8±1.8
11.8±11.6
21.2±13.4
6.7±6.8
26±10.7
35.3±6.7
17.4±10.6
27.2±20.2
23.8±11.1
2.7±2.7
39.3±19
1.4±0.9
1.6±2
9.3±8.6
17.9±15.4
5.3±5.4
25.6±12.2
0.0323
0.6498
0.1600
0.0453
0.1071
0.6129
0.1669
0.3586
0.0840
0.0581
0.1419
0.9254
1
1
1
1
1
1
1
1
1
1
1
1
Online Resource Table 5 Correlation of the tumor methylation level of the 48 genes with ER/PR/HER2 status
Methylation level (mean±SD)
ER
ER
Corrected
Gene
Positive Negative p value1
p value2
(n=131)
(n=49)
ACADL
73.6±7.7 68.8±10.1 5.22E-04
0.0230
ADAMTSL1 18.9±13.0 10.8±9.6 4.38E-05
0.0020
APC
13.1±15.3 11.4±14.8 0.3060
1
BMP6
55.0±6.9 57.9±10.7 0.1522
1
BRCA1
1.3±3.2
5.1±15.4
0.6309
1
BRCA2
0.9±1.2
0.7±0.3
0.4245
1
CADM1
3.4±4.1
3.5±4.2
0.7081
1
CAV1
3.6±4.4
1.9±4.4 1.72E-05 7.91E-04
CCND2
14.1±10.5 11.2±11.0 0.0223
0.8151
CDH1
9.7±3.5
10.3±3.9
0.3106
1
CDKN2A
11.4±11.6 14.2±14.3 0.2350
1
COL1A2
54.0±14.0 60.3±15.2 0.0182
0.6935
CST6
17.0±12.3 12.3±7.8
1
0.0366
DBC1
24.1±11.1 22.9±11.3 0.3725
1
DIRAS3
72.0±16.7 73.8±17.2 0.6207
1
EGFR
23.9±9.8 21.8±10.6 0.1322
1
ESR1
7.4±5.1
9.0±6.6
0.1531
1
ESR2
3.6±7.4
4.1±12.7
0.3447
1
GREM1
20.9±12.3 19.1±13.9 0.2453
1
GSTP1
17.1±4.2 16.0±3.7
0.0648
1
HIC1
4.5±5.9
3.8±4.5
0.3000
1
HRAS
27.0±10.3 26.0±10.1 0.3076
1
ICAM5
14.2±12.2 10.9±12.0 0.0134
0.5493
IGFBP3
20.8±10.9 15.5±10.7 0.0029
0.1233
LAMA3
1.6±2.3
1.6±1.8
0.2251
1
MGMT
94.8±3.0 93.8±5.9
0.3230
1
MLH1
0.7±0.4
0.7±0.4
0.8408
1
NPY
14.3±9.0 10.1±9.4 7.70E-04
0.0331
PDGFRB
21.4±11.5 18.3±13.1 0.0540
1
PGR
4.2±3.4
5.9±5.2
0.8151
0.0220
PPM1E
18.8±11.0 15.0±10.3 0.0163
0.6517
Methylation level (mean±SD)
PR
PR
Corrected
Positive Negative p value1
p value2
(n=107)
(n=73)
73.3±8.5 70.7±8.8
0.2451
0.0056
19.3±12.4 12.9±12.1 8.75E-05
0.0040
13.0±15.1 12.3±15.2 0.6716
1
55.3±7.1 56.4±9.6
0.6674
1
2.0±6.4
2.9±11.0
0.9663
1
0.9±1.1
0.8±0.9
0.2923
1
3.0±3.2
4.1±5.1
0.2528
1
3.8±4.4
2.3±4.4 1.73E-06 8.14E-05
13.9±10.0 12.5±11.6 0.1184
1
9.4±3.2
10.4±4.0
0.0802
1
10.4±11.5 14.8±13.3 0.0077
0.3317
55.2±13.4 56.5±16.2 0.6463
1
17.2±12.5 13.4±9.4
0.0848
1
24.3±11.5 23.1±10.6 0.6579
1
71.8±14.8 73.4±19.6 0.1835
1
24.2±9.5 22.0±10.8 0.1187
1
7.5±5.3
8.3±6.0
0.3086
1
4.0±7.9
3.4±10.6
0.6500
0.0155
20.7±11.6 20.0±14.3 0.3489
1
17.0±4.1 16.7±4.2
0.4655
1
4.4±6.1
4.1±4.7
0.6802
1
27.2±9.7 26.0±11.0 0.3565
1
14.5±12.5 11.4±11.5 0.0361
1
20.5±10.4 17.6±11.9 0.0477
1
1.5±1.9
1.7±2.4
0.3385
1
95.0±2.6 93.7±5.3
0.0833
1
0.7±0.4
0.7±0.4
0.5093
1
13.8±8.7 12.2±10.0 0.0812
1
21.2±11.4 19.6±12.8 0.2492
1
4.3±3.4
5.2±4.8
0.3641
1
19.2±11.3 15.7±10.0 0.0176
0.7235
Methylation level (mean±SD)
HER2
HER2
Corrected
Positive Negative p value1
p value2
(n=46)
(n=112)
73.3±6.2 71.4±9.9
0.6737
1
17.1±13.3 16.9±12.7 0.9725
1
15.3±15.5 11.6±15.2 0.0324
1
55.9±9.2 55.6±8.0
0.8874
1
0.7±0.4
3.1±10.4
0.9238
1
0.7±0.3
1.0±1.3
0.1590
1
3.9±4.4
3.0±3.7
0.2324
1
2.5±4.0
3.3±4.6
1
0.0333
14.2±11.6 12.9±10.7 0.7162
1
10.2±3.9
9.8±3.7
0.5921
1
11.2±13.0 13.1±12.1 0.1779
1
55.5±12.5 55.4±15.3 0.7595
1
17.5±11.3 14.1±10.1 0.0777
1
25.4±10.6 23.0±11.6 0.0745
1
76.6±15.2 71.8±16.6 0.1071
1
23.3±10.9 23.6±9.9
0.8021
1
8.0±4.7
7.4±5.0
0.3787
1
5.3±14.5
3.2±6.4
0.4921
1
23.1±14.1 20.2±12.5 0.2703
1
18.1±5.1 16.3±3.5
1
0.0366
4.7±6.6
4.1±5.4
0.9970
1
28.3±11.3 26.3±9.8
0.3504
1
15.3±13.8 12.7±11.9 0.3367
1
20.1±10.7 18.9±11.2 0.4765
1
1.7±1.8
1.4±1.7
0.3644
1
94.8±2.3 94.5±4.5
0.3850
1
0.8±0.4
0.7±0.4
0.3160
1
15.0±10.4 12.5±8.9
0.2178
1
22.4±11.0 19.3±12.5 0.0470
1
5.7±4.0
4.1±3.9
0.1429
0.0030
20.9±13.7 16.7±9.9
0.0836
1
PRKCDBP
PTGS2
RASSF1
RECK
RUNX3
SFN
SFRP1
SFRP2
SOX17
SYK
TERT
TGFBR2
THBS1
TIMP3
TNFRSF10D
WIF1
WRN
1
8.8±7.8
14.1±10.7
1.0±0.7
53.3±8.7
13.0±13.4
34.4±6.3
16.7±9.8
29.9±17.7
25.3±11.3
2.9±2.9
38.5±16.8
1.5±1.1
1.7±1.7
11.3±11.1
20.6±14.5
6.2±6.7
26.3±11.6
9.1±7.8
0.7687
7.9±9.4 7.99E-06
1.7±5.2
0.5361
52.9±12.8 0.9910
4.6±7.9 1.75E-08
34.7±7.2
0.6796
18.6±13.0 0.5662
24.1±21.6 0.0178
25.9±12.2 0.4339
3.0±3.3
0.5804
37.9±20.8 0.8033
1.7±1.1
0.4043
1.5±2.4
0.2313
8.1±5.7
0.1522
15.8±14.6 0.0250
5.2±4.2
0.5361
24.4±11.1 0.5069
1
3.75E-04
1
1
8.38E-07
1
1
0.6934
1
1
1
1
1
1
0.8745
1
1
8.6±7.6
13.9±10.9
1.0±0.8
53.3±8.9
13.6±13.3
33.8±6.0
17.9±10.3
30.4±17.1
24.8±10.9
3.1±3.0
38.5±15.1
1.6±1.1
1.7±1.7
11.4±10.6
20.4±14.3
6.5±7.1
26.8±11.7
9.2±8.2
0.7898
10.1±10.2 0.0018
1.4±4.3
0.7920
53.0±11.3 0.9454
6.4±10.5 9.81E-08
35.6±7.2
0.0948
16.1±11.4 0.1140
25.2±21.1 0.0246
26.5±12.3 0.3086
2.6±2.9
0.0927
38.1±21.4 0.6030
1.6±1.1
0.9640
1.6±2.2
0.2409
9.1±9.0
0.0398
17.7±15.1 0.1642
5.1±4.1
0.3641
24.4±11.1 0.3611
1
0.0825
1
1
4.71E-06
1
1
0.9839
1
1
1
1
1
1
1
1
1
12.0±11.1
15.1±11.2
1.0±0.9
53.4±9.3
11.3±14.2
34.2±5.8
20.3±12.3
29.6±19.5
29.5±11.8
3.1±3.7
35.2±18.1
1.6±1.0
2.0±2.9
11.0±13.0
19.8±13.5
8.0±8.2
26.3±10.7
7.7±5.9
11.4±10.5
1.0±0.6
52.5±10.3
10.3±11.5
34.4±6.8
16.0±10.0
28.1±19.3
24.5±11.7
2.9±2.7
39.5±17.7
1.5±1.2
1.6±1.6
9.8±7.9
18.7±14.9
5.2±5.1
25.7±11.6
p value calculated with Kruskal-Wallis Rank Sum Test and 2 Corrected p value using the Holm's procedure, p -value<0.05 in bold
0.1448
0.0315
0.1706
0.7888
0.3849
0.7858
0.0318
0.5974
0.0098
0.8154
0.1867
0.2080
0.8783
0.9116
0.5815
0.0673
0.6419
1
1
1
1
1
1
1
1
0.4597
1
1
1
1
1
1
1
1
Online Resource Table 6 Correlation of the tumor methylation level of the 48 genes with P53 mutation, lymph node metastasis status and age
Methylation level (mean±SD)
P53
P53
Corrected
Gene
Positive Negative p value1
p value2
(n=141)
(n=39)
ACADL
72.5±7.8 71.5±11.2 0.8363
1
ADAMTSL1 17.1±12.8 15.3±12.0 0.4275
1
APC
13.6±15.6 9.2±12.9
0.2094
1
BMP6
55.5±8.0 56.7±8.8
0.4885
1
BRCA1
2.3±8.5
2.5±8.9
0.4439
1
BRCA2
0.9±1.2
0.8±0.4
0.5940
1
CADM1
3.5±4.3
3.2±3.4
0.7323
1
CAV1
3.3±4.8
2.6±2.8
0.8635
1
CCND2
13.4±10.7 13.1±10.9 0.7167
1
CDH1
9.8±3.6
10.0±3.7
0.8608
1
CDKN2A
13.2±12.4 8.5±12.3
1
0.0320
COL1A2
55.0±14.8 58.3±13.6 0.1762
1
CST6
15.8±12.0 15.4±9.4
0.5354
1
DBC1
24.2±11.1 22.5±11.3 0.3998
1
DIRAS3
72.7±16.4 71.4±18.4 0.7323
1
EGFR
23.0±10.1 24.4±9.8
0.3115
1
ESR1
7.7±5.7
8.2±5.2
0.4522
1
ESR2
4.0±10.0
2.9±4.7
0.6731
1
GREM1
20.4±12.8 20.3±12.7 0.9765
1
GSTP1
17.0±4.2 16.3±3.7
0.4995
1
HIC1
4.7±6.1
3.1±2.7
0.2107
1
.
7
HRAS
26.7±10.1 26.8±10.8 0.7012
1
ICAM5
13.4±12.2 12.7±12.3 0.3388
1
IGFBP3
19.5±11.1 19.0±11.0 0.8472
1
LAMA3
1.7±2.3
1.4±1.7
0.2673
1
MGMT
94.5±4.2 94.4±3.3
0.4076
1
MLH1
0.7±0.4
0.7±0.4
0.4460
1
NPY
13.1±9.5 13.2±8.7
0.8228
1
PDGFRB
20.6±12.5 20.5±10.0 0.6183
1
PGR
4.8±4.4
4.1±2.5
0.8120
1
PPM1E
17.3±10.4 19.6±12.4 0.2733
1
Methylation level (mean±SD)
Node
Node
Corrected p
positive negative p value1
value2
(n=73)
(n=106)
72.7±7.1 72.0±9.6
0.9953
1
17.4±12.3 16.2±12.9 0.3112
1
12.4±15.3 12.5±14.7 0.5147
1
56.4±8.9 55.4±7.7
0.5165
1
2.1±5.6
2.6±10.2
0.9766
1
0.8±0.4
0.9±1.3
0.7379
1
3.4±4.2
3.5±4.1
0.4867
1
3.1±5.0
3.2±4.0
0.4577
1
11.5±9.7 14.5±11.2 0.0812
1
9.4±3.7
10.1±3.6
0.0628
1
12.0±12.1 12.4±12.7 0.8349
1
58.5±13.7 54.0±14.8 0.0482
1
13.9±9.2 16.8±12.6 0.1633
1
24.3±11.7 23.4±10.8 0.5015
1
75.4±17.4 70.5±16.3 0.0128
0.5740
23.0±11.0 23.4±9.2
0.7512
1
7.2±5.9
8.3±5.4
0.0926
1
4.2±11.5
3.5±7.1
0.3043
1
22.3±13.1 19.0±12.4 0.0870
1
17.0±3.6 16.6±4.4
0.0955
1
4.3±6.5
4.2±4.4
1
0.0479
0.0
79
27.1±11.5 26.5±9.4
0.7939
1
13.2±12.1 13.4±12.4 0.8212
1
18.4±10.1 19.8±11.6 0.5052
1
1.7±2.4
1.5±2.0
0.5052
1
94.2±5.0 94.7±3.2
0.7490
1
0.7±0.4
0.7±0.4
0.8810
1
13.1±9.9 13.1±8.9
0.7646
1
21.8±11.8 19.5±11.9 0.1219
1
3.8±2.4
5.3±4.8
0.0870
1
16.7±11.4 18.5±10.6 0.0683
1
Methylation level (mean±SD)
age<=50
(n=99)
age>50
(n=81)
p value1
Corrected p
value2
71.8±9.4
17±13
10.7±14.1
56±8.6
3.1±10.9
1±1.4
3±2.9
2.6±3.7
13.5±10.9
9.7±3.7
13.6±12.8
56.5±14.1
14.6±10.9
25.2±11.1
72.8±17.6
22.8±9.9
7.9±4.8
2.2±3.4
20±12.7
16.7±4.3
3.5±4.1
26.9±10
11.4±11.4
18.3±11.2
1.8±2.3
94.7±2.8
0.7±0.4
12.3±9.2
19.4±11.6
4.5±4.2
17.5±11.1
72.9±7.6
16.3±12.3
15.1±16
55.4±7.7
1.4±4.1
0.7±0.3
3.9±5.2
3.8±5.1
13.2±10.5
9.9±3.5
10.5±11.8
54.8±15.2
17±12
22.1±11
72±16
23.9±10.2
7.7±6.5
5.6±12.8
20.8±12.8
17±3.9
5.3±6.8
26.5±10.6
15.5±12.8
20.7±10.8
1.4±2
94.3±5.1
0.7±0.4
14.2±9.4
22±12.3
4.9±3.8
18.2±10.8
0.5760
0.7836
0.0694
0.8506
0.9027
0.9301
0.6199
0.1836
0.8495
0.5374
0.0792
0.3628
0.1469
0.0637
0.5460
0.3040
0.3122
0.0937
0.6673
0.3720
0.0055
0.7529
0.0252
0.1121
0.5450
0.6862
0.2519
0.1337
0.1707
0.2413
0.4838
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0.2617
. 7
1
1
1
1
1
1
1
1
1
1
PRKCDBP
PTGS2
RASSF1
RECK
RUNX3
SFN
SFRP1
SFRP2
SOX17
SYK
TERT
TGFBR2
THBS1
TIMP3
TNFRSF10D
WIF1
WRN
1
8.6±7.9
12.1±10.7
1.3±3.1
53.4±10.3
10.1±12.0
34.8±6.7
16.6±9.8
27.5±18.4
25.4±11.6
3.0±3.1
37.6±18.3
1.6±1.1
1.7±2.1
10.3±10.6
19.6±14.9
5.7±6.0
26.2±11.5
10.0±7.7
13.3±11.1
0.9±0.8
52.6±8.6
12.8±15.0
33.4±6.2
19.2±13.5
31.2±20.8
25.9±11.2
2.6±2.3
40.9±16.3
1.6±1.0
1.5±1.1
11.0±7.9
18.5±13.8
6.9±6.6
24.5±11.5
0.1774
0.6257
0.0239
0.5750
0.6643
0.2081
0.4627
0.4115
0.9792
0.8923
0.3388
0.8418
0.1830
0.2599
0.7932
0.2628
.
0.3921
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
9.0±8.3
12.7±10.9
1.4±4.3
53.4±11.3
7.7±10.4
35.6±7.2
18.5±11.7
29.9±19.9
25.4±11.9
2.6±3.1
34.1±16.8
1.5±1.3
1.5±1.5
9.2±11.2
18.9±13.2
5.1±5.6
24.9±11.6
8.8±7.5
12.1±10.7
1.0±0.8
53.0±8.9
12.6±13.8
33.8±6.0
16.4±10.0
27.2±18.3
25.5±11.3
3.1±2.9
41.6±17.8
1.6±0.9
1.8±2.2
11.4±9.2
19.4±15.4
6.5±6.4
26.2±11.3
0.7028
0.7579
0.3269
0.7939
0.0077
0.2560
0.2122
0.3754
0.8212
0.1760
0.0052
0.0828
0.2749
0.0120
0.8418
0.0572
. 7
0.6095
1
1
1
1
0.3616
1
1
1
1
1
0.2496
1
1
0.5514
1
1
1
9±8.6
11±9.2
1±0.8
52±9.3
10.6±13
33.6±6.9
15.9±9.5
28.2±20.3
25.3±11.6
2.6±2.7
38.7±18
1.5±1.2
1.9±2.4
9.9±10
19.3±15.3
5.1±4.5
25.4±11.4
8.7±6.8
14.1±12.2
1.4±4.1
54.7±10.5
10.8±12.5
35.5±6
18.8±11.9
28.4±17.3
25.7±11.5
3.3±3.3
37.9±17.9
1.6±0.9
1.4±1.1
11.1±10.1
19.4±13.9
6.9±7.5
26.2±11.7
p value calculated with Kruskal-Wallis Rank Sum Test and 2 Corrected p value using the Holm's procedure, p value<0.05 in bold
0.7075
0.1707
0.9507
0.0664
0.9920
0.0494
0.1501
0.6736
0.7792
0.0690
0.8823
0.0917
0.6038
0.4469
0.7572
0.1293
. 9
0.4435
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Online Resource Fig. 1